ScreenerHero

NDRA ENDRA Life Sciences Inc.

NAS · US · Healthcare · Diagnostics & Research · endrainc.com
6.060USD+0.33%Mkt Cap: 9.09M $P/E: —

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed …

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$244.79BUSDP/E 36.7
DHR
Danaher Corporation
$153.60BUSDP/E 38.9
NTRA
Natera, Inc.
$57.02BUSD
LONN
Lonza Group AG
$46.01BUSDP/E 38.3
A
Agilent Technologies, Inc.
$47.67BUSDP/E 33.4
WAT
Waters Corporation
$42.81BUSDP/E 110.4
IQV
IQVIA Holdings Inc.
$42.48BUSDP/E 32.1
ILMN
Illumina, Inc.
$40.43BUSDP/E 50.0
IDXX
IDEXX Laboratories, Inc.
$39.97BUSDP/E 35.6
MTD
Mettler-Toledo International Inc.
$30.73BUSDP/E 34.6
LH
Labcorp Holdings Inc.
$25.30BUSDP/E 25.8
DGX
Quest Diagnostics Incorporated
$25.06BUSDP/E 24.1
GH
Guardant Health, Inc.
$22.59BUSD
RVTY
Revvity, Inc.
$17.14BUSDP/E 73.5
MEDP
Medpace Holdings, Inc.
$16.87BUSDP/E 35.5
ERF
Eurofins Scientific SE
$14.23BUSDP/E 26.6
CRL
Charles River Laboratories International, Inc.
$14.34BUSD
ICLR
ICON Public Limited Company
$12.66BUSDP/E 172.7
BIM
bioMérieux S.A.
$10.35BUSDP/E 20.7
QGEN
Qiagen N.V.
$9.25BUSDP/E 22.7

Key Statistics

Company
Market Cap9.09M USD
Enterprise Value7.75M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.03M USD
Revenue/Share—
Last Price6.060 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.99
PEG—
EV/EBITDA-1.17
EV/Revenue—
P/S—
P/B1.44
EPS (TTM)-6.26
EPS (Forward)-3.04
52W Range
2.96045% of range9.850
52W High9.850 USD
52W Low2.960 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-310.93%
ROA-182.35%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.18M USD
CapEx (TTM)3.02M USD
FCF Margin—
FCF Yield-74.08%
Net Debt-1.31M USD
Net Debt/EBITDA0.20
Balance Sheet
Debt/Equity0.22
Current Ratio7.10
Quick Ratio2.21
Book Value/Sh4.21 USD
Cash/Share1.16 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:35
Split DateNov 7, 2024
Analyst Consensus
Rating—
Target (Mean)25.00 USD
Upside (mean)+312.5%
Target Range25.00 USD – 25.00 USD
# Analysts1
Ownership
Shares Out.1.50M
Float1.43M
Insiders13.57%
Institutions17.98%
Short Interest
Short Ratio0.7d
Short % Float2.19%
Short % Out.2.09%
Shares Short31.34K
Short (prev mo.)30.08K
Technical
SMA 505.221 (+16.1%)
SMA 2004.779 (+26.8%)
Beta-0.08
S&P 52W Chg16.45%
Avg Vol (30d)48.35K
Avg Vol (10d)33.55K
Technical Indicators
RSI (14)54.9
MACD0.2141
MACD Signal0.2425
MACD Hist.-0.0285
BB Upper6.457 USD
BB Middle5.955 USD
BB Lower5.454 USD
BB Width16.86%
ATR (14)0.4813 USD
Vol Ratio (20d)0.19x